SAFETY AND EFFICACY OF ADEFOVIR DIPIVOXIL (BIS-POM-PMEA) IN SURVIVAL--HIV

阿德福韦酯 (BIS-POM-PMEA) 对 HIV 生存的安全性和有效性

• 批准号: 6282284
• 负责人: CHERYL L BESCH
• 金额: $ 1.97万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1999-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6282284
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; antiviral agents; chemoprevention; clinical research; cytomegalovirus; human subject; human therapy evaluation; opportunistic infections; prognosis; virus load

The purpose of this study is to determine if the investigational drug bis-POM PMEA is safe to give to people infected with HIV who have a CD4+ cell counts. This study is to also find out if bis-POM PMEA helps slow the growth of HIV and if bis-POM PMEA helps those infected live longer. The study will also look to determine if those not infected with CMV keep from developing CMV and to find out if a special test that looks at how much CMV is in the blood helps to predict which people with CMV may develop CMV disease.

这项研究的目的是确定研究药物是否 BIS-POM PMEA用于CD4+的HIV感染者是安全的 细胞计数。这项研究也是为了找出BIS-POM PMEA是否有助于减缓 艾滋病毒的增长和If bis-POM PMEA有助于那些感染者活得更长。 这项研究还将确定未感染CMV的人是否会继续 开发CMV，并找出一种特殊的测试，看看如何 血液中含有大量CMV有助于预测哪些CMV携带者可能 患上巨细胞病毒病。